Evidence map›Paper›PMID 26811168›Full record

ArticleJournal of the American Heart Association2016

Pretreatment of Cardiac Stem Cells With Exosomes Derived From Mesenchymal Stem Cells Enhances Myocardial Repair.

Zhiwei Zhang, Junjie Yang, Weiya Yan, Yangxin Li, Zhenya Shen, Takayuki Asahara

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhiwei ZhangDepartment of Cardiovascular Surgery of The First Affiliated Hospital & Institute for Cardiovascular Science, Soochow University, Suzhou, China (Z.Z., J.Y., W.Y., Y.L., Z.S.).
Junjie YangDepartment of Cardiovascular Surgery of The First Affiliated Hospital & Institute for Cardiovascular Science, Soochow University, Suzhou, China (Z.Z., J.Y., W.Y., Y.L., Z.S.).
Weiya YanDepartment of Cardiovascular Surgery of The First Affiliated Hospital & Institute for Cardiovascular Science, Soochow University, Suzhou, China (Z.Z., J.Y., W.Y., Y.L., Z.S.).
Yangxin LiDepartment of Cardiovascular Surgery of The First Affiliated Hospital & Institute for Cardiovascular Science, Soochow University, Suzhou, China (Z.Z., J.Y., W.Y., Y.L., Z.S.).
Zhenya ShenDepartment of Cardiovascular Surgery of The First Affiliated Hospital & Institute for Cardiovascular Science, Soochow University, Suzhou, China (Z.Z., J.Y., W.Y., Y.L., Z.S.).
Takayuki AsaharaDepartment of Regenerative Medicine, Tokai University School of Medicine, Kanagawa, Japan (T.A.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExosomes derived from mesenchymal stem cells (MSCs) were proved to boost cell proliferation and angiogenic potency. We explored whether cardiac stem cells (CSCs) preconditioned with MSC exosomes could survive and function better in a myocardial infarction model. METHODS AND

resultsDiI-labeled exosomes were internalized with CSCs. They stimulated proliferation, migration, and angiotube formation of CSCs in a dose-dependent manner. In a rat myocardial infarction model, MSC exosome-preconditioned CSCs had significantly better survival, enhanced capillary density, reduced cardiac fibrosis, and restored long-term cardiac function. MicroRNA profiling analysis revealed that a set of microRNAs were significantly changed in CSCs after MSC exosome treatment.

conclusionsPretreatment of CSCs with MSC exosomes provided a promising strategy to improve survival and angiogenic potency of CSCs.

Indexed as

Neovascularization, PhysiologicRegenerationAnimalsAnimals, NewbornCell DifferentiationCell MovementCell ProliferationCells, CulturedDisease Models, AnimalEndothelial Progenitor CellsExosomesFibrosisGene Expression RegulationGene Regulatory NetworksMesenchymal Stem CellsMicroRNAsMicroRNAsangiogenesiscardiac stem cellsexosomesmiRNA profilingproliferation

Identifiers

PMID26811168
PMCPMC4859399

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.